ViroPharma Incorporated (Nasdaq: VPHM) today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®. The Ryze Above program was created for HAE patients prescribed Cinryze, the first and only drug specifically approved to help prevent swelling and/or painful attacks in teenagers and adults with HAE.
'Ryze Above' is designed to meet the individual needs of patients with HAE enrolled in the CINRYZESolutions support program and are either receiving Cinryze as prophylaxis against their disease or awaiting initiation of therapy. The program provides educational information about HAE, patient support services, information about Cinryze and the importance of disease prevention, and information on CINRYZESolutions. Through 'Ryze Above', important resources, interactive tools, and services are available throughout therapy with Cinryze, and can help patients in managing the challenges of living with HAE.
Patients are automatically enrolled in the 'Ryze Above' patient resources program when they enroll in CINRYZESolutions. Patients will have access to starter kits, travel kits, exclusive online educational materials, resources, and will receive personalized program communications from their 'Ryze Above' program administrators.
Patients in 'Ryze Above' will receive a starter kit, including: